Welcome to our dedicated page for Smith & Nephew news (Ticker: SNN), a resource for investors and traders seeking the latest updates and insights on Smith & Nephew stock.
Smith & Nephew plc (NYSE: SNN, LSE: SN) is a global medical technology business whose news flow reflects activity across orthopaedics, sports medicine & ENT, and advanced wound management. Company announcements frequently highlight new product launches, clinical evidence, strategic partnerships and portfolio updates that are relevant to surgeons, healthcare providers and investors following SNN stock.
Recent news has showcased advanced wound management innovations, such as clinical data on the PICO◊ Single Use Negative Pressure Wound Therapy System demonstrating reductions in wound dehiscence, length of stay and costs versus an alternative device in orthopaedic and cardiovascular surgery, and studies on the ALLEVYN™ COMPLETE CARE 5-Layer Foam Dressing describing its mechanism in absorbing and dissipating shear forces linked to pressure injury risk.
In Sports Medicine, Smith+Nephew news items have covered the REGENETEN◊ Bioinductive Implant, including randomized controlled trial results and expanded indications to extra-articular ligament injuries, as well as updates on the CARTIHEAL◊ AGILI-C◊ Cartilage Repair Implant, including the establishment of a Category I CPT code recognising its clinical significance and adoption. Announcements also describe launches such as the Q-FIX™ KNOTLESS All-Suture Anchor and the CENTRIO Platelet-Rich-Plasma System for chronic exuding wounds.
Orthopaedics-related releases include the launch of the TRIGEN™ MAX Tibia Nailing System for tibial fractures and the expansion of CORIOGRAPH™ Pre-Op Planning and Modeling Services to total shoulder arthroplasty, alongside references to the AETOS◊ Shoulder System. Strategic and investor-focused news covers topics such as the RISE strategy, medium-term financial targets, and acquisitions like Integrity Orthopaedics and its Tendon Seam™ rotator cuff repair technology.
Visitors to this SNN news page can review these updates in one place, tracking how Smith & Nephew presents clinical data, regulatory milestones, portfolio expansions, partnerships with organisations such as UFC and Wimbledon, and capital markets communications that shape the company’s profile in the global medical technology sector.
Smith+Nephew (NYSE: SNN) launched ARIA, a digital platform aimed at enhancing patient care by improving communication between patients and providers during surgical episodes. Powered by the Real Intelligence ecosystem, ARIA helps reduce recovery times, minimize costs, and gather Patient Reported Outcome Measures (PROMs). The platform integrates secure communication and customizable pathways, leading to actionable data for surgery centers and enhancing efficiencies. Prior technology acquisitions are foundational to ARIA's capabilities, including a documented 45% reduction in readmissions in previous implementations.
On July 28, 2020, Smith+Nephew (NYSE: SNN) launched the RI.HIP NAVIGATION technology for total hip arthroplasty (THA). This system enhances surgical accuracy through patient-specific component alignment, following the acquisition of Brainlab's Orthopaedic Joint Reconstruction business in May 2019. The POLAR3™ Primary Total Hip System, known for delivering a 98% survivorship rate at 8 years, integrates with Brainlab's platform used in over 500 hospitals. This innovation received FDA clearance and CE Mark certification, aiming to improve patient outcomes while being cost-efficient for hospitals and ASCs.
Smith+Nephew (NYSE:SNN) announced a significant milestone with over two million patients treated using their OXINIUM Technology, a proprietary oxidized zirconium alloy for hip and knee replacements. OXINIUM offers a combination of metal strength and ceramic wear resistance, enhancing durability and performance in joint applications.
Clinical data highlights OXINIUM's superiority, including 29% reduction in revision risk post arthroplasty and results from 45 million cycles in wear testing. This technology underpins advanced products like POLAR3 and JOURNEY II, reflecting Smith+Nephew's commitment to innovation in orthopaedics.
Smith+Nephew (NYSE:SNN) announced on June 16, 2020, that its REGENETEN Bioinductive Implant has received CE Mark certification, allowing its use in key European markets. This implant has been pivotal in over 40,000 procedures in the US, enhancing approaches to rotator cuff surgery. The implant, which aids natural healing by promoting tendon-like tissue growth, will be available for over 310,000 annual rotator cuff procedures in Europe, a market worth approximately $175 million. The company aims to transform patient outcomes with this innovative technology.